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Cretinism	– lack	of	iodine	in	the	diet,	leading	to	
thyroid	hormone	deficiency.
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Down	Syndrome
Down	Syndrome
Christopher	Joseph	"Chris"	Burke	(born	August	
26,	1965)	is	an	American	actor	and	folk	singer,	
who	lives	with	Down	syndrome,	who	has	
become	best	known	for	his	character	Charles	
"Corky"	Thacher on	the	television	series	Life	
Goes	On.
And	there	are	people	with	Mosaic	Down	
Syndrome,	who	are	much	less	affected.
Velocardiofacial (22q11.2)	Syndrome


Population Stratification is from the 
migration patterns of  haplotypes
throughout human history
Charles	Darwin
1809-1882
Frances	Galton
1822-1911
Gregor Mendel
1822-1884

Walter	Frank	Raphael	Weldon
1860-1906
William	Bateson
1861-1926
Karl	Pearson
1857-1936

Beyond	our	Kuhnian inheritance
A	recent	lecture	by	Prof	Greg	Radick questions	our	scientific	inheritance,	
through	textbook	histories	of	genetics	and	Thomas	Kuhn's	legacy
http://www.guardian.co.uk/science/the-h-word/2012/aug/28/thomas-
kuhn
Walter	Frank	Raphael	Weldon
Vs.	
William	Bateson
Forthcoming	by	Greg	Radick.	Scholarly	edition	of	W.	F.	R.	Weldon's	Theory	of	
Inheritance	(1904-1905),	coedited	with	Annie	Jamieson.
Mendel’s laws of alternative inheritance in peas 29 
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• “The	fundamental	mistake	which	vitiates	all	work	
based	upon	Mendel’s	method	is	the	neglect	of	ancestry,	
and	the	attempt	to	regard	the	whole	effect	upon	
offspring,	produced	by	a	particular	parent,	as	due	to	
the	existence	in	the	parent	of	particular	structural	
characters;	while	the	contradictory	results	obtained	by	
those	who	have	observed	the	offspring	of	parents	
apparently	identical	in	certain	characters	show	clearly	
enough	that	not	only	the	parents	themselves,	but	their	
race,	that	is	their	ancestry,	must	be	taken	into	account	
before	the	result	of	pairing	them	can	be	predicted”	–
Walter	Frank	Raphael	Weldon	(Weldon,	1902).

“Biological	Indeterminacy”
• Bateson	became	famous	as	the	outspoken	
Mendelian antagonist	of	Walter	Raphael	Weldon,	
his	former	teacher,	and	Karl	Pearson who	led	the	
biometric school	of	thinking.	This	concerned	the	
debate	over	saltationism versus	gradualism
(Darwin	had	been	a	gradualist,	but	Bateson	was	a	
saltationist).	Later,	Ronald	Fisher and	J.B.S.	
Haldane showed	that	discrete	mutations	were	
compatible	with	gradual	evolution:	see	the	
modern	evolutionary	synthesis.
Biological	Indeterminacy. Greenspan	RJ.	Sci Eng
Ethics.	2012	Jul	3
Biological	Robustness.
The	canalisation metaphor	suggests	that	phenotypes	are	very	robust	to	small	perturbations,	
for	which	development	does	not	exit	the	canal,	and	rapidly	returns	back	down,	with	little	
effect	on	the	final	outcome	of	development.	But	perturbations	whose	magnitude	exceeds	a	
certain	threshold	will	break	out	of	the	canal,	moving	the	developmental	process	into	
uncharted	territory.	Strong	robustness	up	to	a	limit,	with	little	robustness	beyond,	is	a	pattern	
that	could	increase	evolvability in	a	fluctuating	environment.
E.	coli	adapting	to	low	glucose	conditions,	in	the	context	of	media	containing	citrate.	
– Richard	Lemski experiment	
"Finally,	novel	functions	often	emerge	in	rudimentary	forms	that	must	be	refined	to	
exploit	the	ecological	opportunities.	This	three-step	process	— in	which	
potentiation	makes	a	trait	possible,	actualization	makes	the	trait	manifest,	and	
refinement	makes	it	effective	— is	probably	typical	of	many	new	functions.”	- Lemski
Genotype	≠	Phenotype
Environment	matters!
Ancestry	matters!
Genomic	background	matters!
Longitudinal	course	matters!
Categorical	Thinking	Misses	Complexity
A	conceptual	model	of	genotype-phenotype	correlations.		The	y plane	represents	a	
phenotypic	spectrum,	the	x plane	represents	the	canalized	progression	of	development	
through	time,	and	the	z plane	represents	environmental	fluctuations.		
Time
Environment
Phenotypic
Spectrum


Proteus	syndrome	results	from	a	
mutation	in	the	AKT1	gene.	This	
genetic	change	is	not	inherited	
from	a	parent;	it	arises	randomly	in	
one	cell	during	the	early	stages	of	
development	before	birth.	As	cells	
continue	to	grow	and	divide,	some	
cells	will	have	the	mutation	and	
other	cells	will	not.	This	mixture	of	
cells	with	and	without	a	genetic	
mutation	is	known	as	mosaicism.
“Superpower”	mutations???
LRP5	mutation
D111Y,	G171R,	A214T,	A214V,	A242T,	and	
T253I		
Myostatin mutation	
Exon	2	allele	 P198A
**Thanks	to	George	Church	for	discussions	on	this.
Another&example:&Liam&Hoekstra,&known&as&the&world's&strongest&
toddler&at&age&3,&has&a&condi)on&called&myosta)n4related&muscle&
hypertrophy&which&results&in&increased&muscle&mass&and&reduced&body&
fat.&Myosta)n4related&muscle&hypertrophy,&or&muscle&enlargement,&is&
an&extremely&rare&gene)c&condi)on.&–&How&rare???&&
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hours after birth, and the infant was admitted to
the neonatal ward for assessment. He appeared ex-
traordinarily muscular, with protruding muscles
in his thighs (Fig. 1A) and upper arms. With the
exception of increased tendon reflexes, the physi-
cal examination was normal. Hypoglycemia and
increased levels of testosterone and insulin-like
growth factor I were excluded. Muscular hypertro-
phy was verified by ultrasonography when the in-
fant was six days of age (Fig. 1B and 1C). Doppler
echocardiography and electrocardiography per-
formed soon after birth and every six months there-
after were consistently normal. At 4.3 years of age
(body-surface area, 0.78 m
 
2
 
), the child had a pulse
rate of 95 beats per minute, a left ventricular ejection
fraction of 70 percent, fractional shortening at the
midwall of 56 percent, and a cardiac output of 2.81
liters per minute, with a left ventricular measure-
ment of 3.42 cm during diastole (50th percentile)
and 1.99 cm (25th percentile) during systole and
respective septal measurements of 0.59 cm (75th
percentile) and 0.81 cm (75th percentile).
The stimulus-induced myoclonus gradually sub-
sided after two months. The child’s motor and
mental development has been normal. Now, at 4.5
years of age, he continues to have increased muscle
bulk and strength, and he is able to hold two 3-kg
dumbbells in horizontal suspension with his arms
extended.
Several family members (Fig. 1D) have been re-
ported to be unusually strong. Family member II-3
was a construction worker who was able to unload
curbstones by hand. The 24-year-old mother of the
child (III-5) appeared muscular, though not to the
extent observed in her son; she did not report any
health problems. No family members aside from
the mother were available to provide samples for
genetic analysis.
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Figure 1. Photographs of the Child at the Ages of Six Days 
and Seven Months (Panel A), Ultrasonograms (Panel B) 
and Morphometric Analysis (Panel C) of the Muscles 
of the Patient and a Control Infant, and the Patient’s 
Pedigree (Panel D).
 
The arrowheads in Panel A indicate the protruding mus-
cles of the patient’s thigh and calf. In Panel B, an ultra-
sonographic transverse section (linear transducer, 10 
MHz) through the middle portion of the thigh reveals 
differences between the patient and a control infant of 
the same age, sex, and weight. VL denotes vastus latera-
lis, VI vastus intermedius, VM vastus medialis, RF rectus 
femoris, and F femur. In Panel C, retracings of the mus-
cle outlines and results of the morphometric analysis of 
the muscle cross-sectional planes of the two infants also 
reveal marked differences. Panel D shows the patient’s 
pedigree. Solid symbols denote family members who are 
exceptionally strong, according to information in their 
clinical history. Square symbols denote male family 
members, and circles female family members.
The New England Jour al of Medicine 
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uscle wasting and weakness are among the most common
 
 
 
in-
 
herited and acquired disorders and include the muscular dystrophies,
cachexia, and ag -related wasting. Since there is no generally accepted
treatment to i prove muscle bulk and strength, these conditions pose a substantial
burden to patients as well as to public health. Consequently, there has been consider-
able interest in a recently described inhibitor of muscle growth, myostatin, or growth/
differentiation factor 8 (GDF-8), which belongs to the transforming growth factor 
 
b
 
superfamily of secreted proteins that control the growth and differentiation of tissues
throughout the body. The myostatin gene is expressed almost exclusively in cells of
skeletal-muscle lineage throughout embryonic development as well as in adult ani-
mals and functions as a negative regulator of muscle growth.
 
1,2
 
 Targeted disruption of
the myostatin gene in mice doubles skeletal-muscle mass.
 
1
 
 Conversely, systemic over-
expression of the myostatin gene leads to a wasting syndrome characterized by ex-
tensive muscle loss.
 
3
 
 In adult animals, myostatin appears to inhibit the activation of
satellite cells, which are stem cells resident in skeletal muscle.
 
4,5
 
The potential relevance of myostatin to the treatment of disease in humans has been
suggested by studies involving 
 
mdx
 
 mi e, which carry a mutation in the dystrophin gene
and therefore serve as a genetic model of Duchenne’s and Becker’s muscular dystro-
phy.
 
6
 
 For example
 
, mdx
 
 mice that lacke  myost tin were foun  not only to be stronger
and more muscular than their
 
mdx
 
 counterparts with normal myostatin, but also to have
reduced fibrosis and fatty remodeling, suggesting mproved regeneration of us-
cle.
 
7
 
 Furthermore, injection of neutralizing monoclonal antibodies directed against
myostatin into either wild-type or 
 
mdx
 
 mice increases mus le mass and specific force,
suggesting that myostatin plays an important role in regulating muscle growth in adult
animals.
 
8,9
 
The function of myostatin appears to be conserved across species, since mutations
in the myostatin gene have been shown to be responsible for the “double-muscling”
phenotype in cattle.
 
10-13 
 
The phenotypes of mice and cattle lacking myostatin and the
high degree of sequence conservation of the predicted myostatin protein in many mam-
malian species have raised the possibility that myostatin may help regulate muscle
growth in humans. We report the identification of a myostatin mutation in a child with
muscle hypertrophy, thereby providing strong evidence that myostatin does play an im-
portant role in regulating muscle mass in humans.
A healthy woman who was a former professional athlete gave birth to a son after a nor-
mal pregnancy. The identity of the child’s father was not revealed. The child’s birth
weight was in the 75th percentile. Stimulus-induced myoclonus developed several
m
case report
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Belgian	Blue is	a	breed	of	beef cattle from	Belgium.	The	Belgian	Blue	
has	a	natural	mutation in	the	myostatin gene	which	codes	for	the	
protein,	myostatin.
http://en.wikipedia.org/wiki/Belgian_Blue
A Mutation in the Myostatin Gene
Increases Muscle Mass and Enhances
Racing Performance in Heterozygote Dogs
Dana S. Mosher1, Pascale Quignon1, Carlos D. Bustamante2, Nathan B. Sutter1, Cathryn S. Mellersh3, Heidi G. Parker1,
Elaine A. Ostrander1*
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Computational Biology, Cornell University, Ithaca, New York, United States of America, 3 Animal Health Trust, Center for Preventive Medicine, Newmarket, United Kingdom
Double muscling is a trait previously described in several mammalian species including cattle and sheep and is caused
by mutations in the myostatin (MSTN) gene (previously referred to as GDF8). Here we describe a new mutation inMSTN
found in the whippet dog breed that results in a double-muscled phenotype known as the ‘‘bully’’ whippet. Individuals
with this phenotype carry two copies of a two-base-pair deletion in the third exon ofMSTN leading to a premature stop
codon at amino acid 313. Individuals carrying only one copy of the mutation are, on average, more muscular than wild-
type individuals (p ¼ 7.43 3 10"6; Kruskal-Wallis Test) and are significantly faster than individuals carrying the wild-
type genotype in competitive racing events (Kendall’s nonparametric measure, s¼ 0.3619; p ’ 0.00028). These results
highlight the utility of performance-enhancing polymorphisms, marking the first time a mutation in MSTN has been
quantitatively linked to increased athletic performance.
Citation: Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, et al. (2007) A mutation in the myostatin gene increases muscle mass and enhances racing
performance in heterozygote dogs. PLoS Genet 3(5): e79. doi:10.1371/journal.pgen.0030079
Introduction
The wide variety of behaviors and morphological types
exhibited among dog breeds and the overall low genetic
diversity within each breed make the dog an excellent genetic
system for mapping traits of interest [1,2]. Recently, owners of
whippets, an established racing-dog breed, have reported a
phenotype of heavy muscling occurring within the breed
(http://www.k9community.co.uk/forums/index.php). The typi-
cal whippet is similar in conformation to the greyhound, a
medium-sized sighthound, weighing about 9 kg and charac-
terized by a slim build, long neck, small head, and pointed
snout (Figure 1A) [3]. Heavily muscled dogs, termed ‘‘bully’’
whippets by breeders, have broad chests and unusually well-
developed leg and neck musculature (Figure 1C). ‘‘Bully’’
whippets are easily distinguished from their normal litter-
mates based on physical appearance alone (compare Figure
1A and 1C). Owners report that ‘‘bully’’ whippets do not have
any health abnormalities other than muscle cramping in the
shoulder and thigh. However, the dogs are often euthanized
at an early age as they do not conform to the American
Kennel Club breed standard. In addition, about 50% of
‘‘bully’’ whippets have a distinctive overbite.
The ‘‘bully’’ whippet phenotype is reminiscent of the
double muscling phenotype seen in other species that is
caused by mutations in the myostatin (MSTN) gene. Such
variants have been observed in mice [4], cattle [5,6], sheep [7],
and human, the latter described once in a German boy [8].
The myostatin protein has been shown to affect both the
amount and composition of muscle fibers. For instance, the
muscle mass of Mstn knockout mice is two to three times
greater than that of wild-type mice [9]. Furthermore, the
sequence of the MSTN gene is relatively conserved across
species [9]. Therefore, we chose to interrogate theMSTN gene
for possible mutations resulting in the ‘‘bully’’ whippet
phenotype.
Results
MSTN Genotypes in the Whippet
We sequenced the three exons and the majority of introns
of the MSTN gene in an initial set of 22 whippets. A 2-bp
deletion was discovered in the third exon of the MSTN gene
(Figure 2). This deletion removes nucleotides 939 and 940
within exon three and leads to a premature stop codon at
amino acid 313 instead of the normal cysteine, removing 63
aa from the predicted 375-aa protein. The lost cysteine is one
of several highly conserved cysteines known to form disulfide
dimers required for protein function [9].
Of the 22 whippets sequenced, all ‘‘bully’’ whippets tested
(n ¼ 4) were homozygous for the deletion (mh/mh) while all
dogs that sired or whelped a ‘‘bully’’ whippet (n ¼ 5) were
heterozygous for the deletion (mh/þ). None of the initial set of
13 normal-appearing whippets that lacked a family history of
the ‘‘bully’’ phenotype carried the deletion; these dogs were
designated wild type (þ/þ). An additional set of DNA samples
from 146 whippets (both racers and nonracers) were collected
at racing events and through the mail without regard to the
dogs’ family histories of the ‘‘bully’’ phenotype. These were
Editor: Joseph S. Takahashi, Northwestern University, United States of America
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codon at amino acid 313. Individuals carrying only one copy of the mutation are, on average, more muscular than wild-
type individuals (p ¼ 7.43 3 10"6; Kruskal-Wallis Test) and are significantly faster than individuals carrying the wild-
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Introduction
The wide variety of behaviors and morphological types
exhibited among dog breeds and the overall low genetic
diversity within each breed make the dog an excellent genetic
system for mapping traits of interest [1,2]. Recently, owners of
whippets, an established racing-dog breed, have reported a
phenotype of heavy muscling occurring within the breed
(http://www.k9community.co.uk/forums/index.php). The typi-
cal whippet is similar in conformation to the greyhound, a
medium-sized sighthound, weighing about 9 kg and charac-
terized by a slim build, long neck, small head, and pointed
snout (Figure 1A) [3]. Heavily muscled dogs, termed ‘‘bully’’
whippets by breeders, have broad chests and unusually well-
developed leg and neck musculature (Figure 1C). ‘‘Bully’’
whippets are easily distinguished from their normal litter-
mates based on physical appearance alone (compare Figure
1A and 1C). Owners report that ‘‘bully’’ whippets do not have
any health abnormalities other than muscle cramping in the
shoulder and thigh. However, the dogs are often eut aniz d
at an early age as they do not conform to the American
Kennel Club breed standard. In addition, about 50% of
‘‘bully’’ whippets have a distinctive overbite.
The ‘‘bully’’ whippet phenotype is reminiscent of the
double muscling phenotype seen in other species that is
caused by mutations in the myostatin (MSTN) gene. Such
variants have been observed in mice [4], cattle [5,6], sheep [7],
and human, the latter described once in a German boy [8].
The myostatin protein has been shown to affect bot the
amount and composition of muscle fibers. For instance, the
muscle mass of Mstn knockout mice is two to three times
greater than that of wild-type mice [9]. Furthermore, the
sequence of the MSTN gene is relatively conserved across
species [9]. Therefore, we chose to interrogate theMSTN g ne
for possible mutations resulting in the ‘‘bully’’ whippet
phenotype.
Results
MSTN Genotypes in the Whippet
We sequenced the three exons and the majority of introns
of the MSTN gene in an initial set of 22 whippets. A 2-bp
deletion was discovered in the third exon of the MSTN gene
(Figure 2). This deletion removes nucleotides 939 and 940
within exon three and leads to a premature stop codon at
amino acid 313 instead of the normal cysteine, removing 63
aa from the predicted 375-aa protein. The lost cysteine is one
of several highly conserved cysteines known to form disulfide
dimers required for protein function [9].
Of the 22 whippets sequenced, all ‘‘bully’’ whippets tested
(n ¼ 4) were homozygous for the deletion (mh/mh) while all
dogs that sired or whelped a ‘‘bully’’ whippet (n ¼ 5) were
heterozygous for the deletion (mh/þ). None of the initial set of
13 normal-appearing whippets that lacked a family history of
the ‘‘bully’’ phenotype carried the deletion; these dogs were
designated wild type (þ/þ). An additional set of DNA samples
from 146 whippets (both racers and nonracers) were collected
at racing events and through the mail without regard to the
dogs’ family histories of the ‘‘bully’’ phenotype. These were
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Introduction
The wide variety of behaviors and morphological types
exhibited among dog breeds and the overall low genetic
diversity within each breed make the dog an excellent genetic
system for mapping traits of interest [1,2]. Recently, owners of
whippets, an established racing-dog breed, have reported a
phenotype of heavy muscling occurring within the breed
(http://www.k9community.co.uk/forums/index.php). The typi-
cal whippet is similar in conformation to the greyhound, a
medium-sized sighthound, weighing about 9 kg and charac-
terized by a slim build, long neck, small head, and pointed
snout (Figure 1A) [3]. Heavily muscled dogs, termed ‘‘bully’’
whippets by breeders, have broad chests and unusually well-
developed leg and neck musculature (Figure 1C). ‘‘Bully’’
whippets are easily distinguished from their normal litter-
mates based on physical appearance alone (compare Figure
1A and 1C). Owners report that ‘‘bully’’ whippets do not have
any health abnormalities other than muscle cramping in the
shoulder and thigh. However, the dogs are often euthanized
at an early age as they do not conform to the American
Kennel Club breed standard. In addition, about 50% of
‘‘bully’’ whippets have a distinctive overbite.
The ‘‘bully’’ whippet phenotype is reminiscent of the
double muscling phenotype seen in other species that is
caused by mutations in the myostatin (MSTN) gene. Such
variants have been observed in mice [4], cattle [5,6], sheep [7],
and human, the latter described once in a German boy [8].
The myostatin protein has been shown to affect both the
amount and composition of muscle fibers. For instance, the
muscle mass of Mstn knockout mice is two to three times
greater than that of wild-type mice [9]. Furthermore, the
sequence of the MSTN gene is relatively conserved across
species [9]. Therefore, we chose to interrogate theMSTN gene
for possible mutations resulting in the ‘‘bully’’ whippet
phenotype.
Results
MSTN Genotypes in the Whippet
We sequenced the three exons and the majority of introns
of the MSTN gene in an initial set of 22 whippets. A 2-bp
deletion was discovered in the third exon of the MSTN gene
(Figure 2). This deletion removes nucleotides 939 and 940
within exon three and leads to a premature stop codon at
amino acid 313 instead of the normal cysteine, removing 63
aa from the predicted 375-aa protein. The lost cysteine is one
of several highly conserved cysteines known to form disulfide
dimers required for protein function [9].
Of the 22 whippets sequenced, all ‘‘bully’’ whippets tested
(n ¼ 4) were homozygous for the deletion (mh/mh) while all
dogs that sired or whelped a ‘‘bully’’ whippet (n ¼ 5) were
heterozygous for the deletion (mh/þ). None of the initial set of
13 normal-appearing whippets that lacked a family history of
the ‘‘bully’’ phenotype carried the deletion; these dogs were
designated wild type (þ/þ). An additional set of DNA samples
from 146 whippets (both racers and nonracers) were collected
at racing events and through the mail without regard to the
dogs’ family histories of the ‘‘bully’’ phenotype. These were
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Introduction
The wide variety of behaviors and orphologic l ty es
exhibited among dog bre ds and the overall low genetic
diversity within each breed make the dog an excellent genetic
system for mapping traits of interest [1,2]. Recently, owners of
whippets, an established racing-dog breed, have reported a
phenotype of heavy muscling occurring within the breed
(http://www.k9community.co.uk/forums/index.php). The typi-
cal whippet is similar in conformation to the greyhound, a
medium-sized sighthound, weighing about 9 kg and charac-
terized by a slim build, long neck, small head, and poin ed
snout (Figure 1A) [3]. Heavily muscled dogs, termed ‘‘bul y’’
whippets by breeders, have broad chests and unusually well-
developed leg and neck musculature (Figure 1C). ‘‘Bully’’
whippets are easily distinguis ed from their normal litter-
mates based on physical appearance alone (compar Figure
1A and 1C). Owners report that ‘‘bully’’ whippets do not have
any health bnormalitie other th n muscle cramping in th
sh ulder and thigh. However, the dogs are often euthanized
at an early age as they do not conform to the American
Kennel Club breed standard. In addition, about 50% of
‘‘bully’’ whippets have a distinctive overbite.
The ‘‘bully’’ whippet phenotype is eminiscent of the
double muscling phenotype seen in other species that is
caused by mutations in the myostatin (MSTN) gene. Such
variants have been observed in mice [4], cattle [5,6], sheep [7],
and human, the latter described once in a German boy [8].
The myostatin protein has be shown to affect both the
amount and composition of muscle fibers. For instance, the
muscle mass of Mstn knockout mice is two to three times
greater than that of wild-type mice [9]. Furthermore, the
sequence of the MSTN gene is relatively conserved across
species [9]. Therefore, we chose to interrogate theMSTN gene
for possible mutations resulting in the ‘‘bully’’ whippet
phenotype.
Results
MSTN Genotypes n the Whipp t
We sequenc d the three exons and the majority of introns
of the MSTN gene in an initial set of 22 whippets. A 2-bp
deletion was discovered in the third exon of the MSTN gene
(Figure 2). This deletion removes nucleotides 939 and 940
within exon three and leads to a premature stop codon at
amino acid 313 instead of the normal cysteine, removing 63
aa from the predicted 375-aa protein. The lost cysteine is one
of several highly conserved cysteines known to form disulfide
dimers required for protein function [9].
Of the 22 whippets sequenced, all ‘‘bully’’ whippets tested
(n ¼ 4) were homozygous for the deletion (mh/mh) while all
dogs that sired or whelped a ‘‘bully’’ whippet (n ¼ 5) were
heterozygous for the deletion (mh/þ). None of the initial set of
13 normal-appearing whippets that lacked a family history of
the ‘‘bully’’ phenotype carried the deletion; these dogs were
designated wild type (þ/þ). An additional set of DNA samples
from 146 whippets (both racers and nonracers) were collect d
at racing events and through the mail without regard to the
dogs’ family histories of the ‘‘bully’’ phenotype. These were
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Introduction
The wide variety of behaviors and morphological types
exhib ted among dog breeds and the verall low genetic
diversity within each breed make the dog a excellent genetic
system for mapping traits of interest [1,2]. Recently, owners of
whippets, an established racing-dog breed, have reported a
phenotype of heavy muscling occurring within the breed
(http://www.k9community.co.uk/forums/index.php). The typi-
cal whippet is similar in conformation to the greyhound, a
medium-sized sighthound, weighing about 9 kg and charac-
terized by a slim build, long neck, small head, and pointed
snout (Figure 1A) [3]. Heavily muscled dogs, termed ‘‘bully’’
whippets by breeders, have broad chests and unusually well-
developed leg and neck musculature (Figure 1C). ‘Bu ly ’
whippets are eas ly distinguished from their normal litt r-
mates ba ed on ysical appearance alon (compare Figure
1A and 1C). Owner report that ‘‘bully’’ whippets do ot have
any health abnormalities other than muscle cramping in the
shoulder and thigh. However, the dogs are often eut aniz d
at an early age as they do not conform to the American
Kennel Club breed standard. In addition, about 50% of
‘‘bully’’ whippets have a distinctive overbite.
The ‘‘bully’’ whippet phenotype is reminiscent of the
double muscling phenotype seen in other species that is
caused by mutations in the myostatin (MSTN) ge e. Such
variants have been observed in mice [4], cattle [5,6], sheep [7],
and human, the latter described once in a German boy [8].
The myostatin protein has been shown to affect bot the
amount and composition of muscle fibers. For instance, the
muscle mass of Mstn knockout mice is two to three times
greater than that of wild-type mice [9]. Furthermore, the
sequence of the MSTN gene is relatively conserved across
species [9]. Therefore, we chose to interrogate theMSTN g ne
for possible mutations resulting in the ‘‘bully’’ whippet
phenotype.
Results
MSTN Genotypes in the Whippet
We sequenced the three exons and the majority of introns
of the MSTN gene in an initial s t of 22 whippets. A 2-bp
deletion was discovered in the third exon of the MSTN gene
(Figur 2). This deletion removes nucleotides 939 and 940
within exon three and leads to a p e ature stop codon at
amino acid 313 instead of the normal cysteine, removing 63
aa from the predicted 375-aa protein. The lost cysteine is one
of several highly conserved cysteines known to form disulfide
dimers required for protein function [9].
Of the 22 whippets sequenced, all ‘‘bully’’ whippets tested
(n ¼ 4) were homozygous for the deletion (mh/mh) while all
dogs that sired or whelped a ‘‘bully’’ whippet (n ¼ 5) were
heterozygous for the deletion (mh/þ). None of the initial set of
13 normal-appearing whippets that lacked a family history of
the ‘‘bully’’ phenotype carried the deletion; these dogs were
designated wild type (þ/þ). An additional set of DNA samples
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at racing eve ts and through the mail without regard to the
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Vignette	#1:	Discovering	a	new	
syndrome	and	its	genetic	basis.
Ogden	Syndrome
We	found	the	SAME	mutation	in	two	unrelated	families,	with	a	very	similar	
phenotype	in	both	families,	helping	prove	that	this	genotype	contributes	to	the	
phenotype	observed.
First	boy.	Called	“a	little	old	man”	by	
the	family.	Died	around	~1	year	of	
age,	from	cardiac	arrhythmias.
This	is	the	first	boy	in	the	late	1970’s.
prominence	of	eyes,	down-sloping	palpebral	fissures,	thickened	
eyelids,	large	ears,	beaking of	nose,	flared	nares,	hypoplastic nasal	
alae,	short	columella,	protruding	upper	lip,	micro-retrognathia
This	is	the	“Proband”	photograph	presented	at	Case	Conference.
II-1 III-2
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C D
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These	are	the	Major	Features	of	the	Syndrome.
Vignette	#2:	New	Syndrome	with	
Mental	Retardation,	“Autism”,	“ADHD”
Likely	X-linked	or	Autosomal	Recessive,	with	X-linked	being	supported	by	extreme	X-
skewing	in	the	mother	
1.5	years	old																										3.5	years	old
3	years	old																																			5	years	old
Dysmorphic
Mental	Retardation
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Understanding the spectrum of allelic variation in human genes and 
revealing the demographic and evolutionary forces that shape this varia-
tion within and among populations is a major aim of human genetics 
research. Such information is critical for defining the architecture of 
common diseases, identifying functionally important variation, and ulti-
mately facilitating the interpretation of personalized disease risk profiles 
(1–3). To date, surveys of human variation have been dominated by 
studies of single nucleotide polymorphisms (SNPs) genotyped using 
high-density arrays composed of common variants (4–6). While these 
projects have substantially improved our knowledge of common allelic 
variation and enabled genome-wide association studies (GWAS), they 
have been generally uninformative about the population genetics charac-
teristics of rare variants, defined here as a minor allele frequency (MAF) 
of less than 0.5%. 
Rare genetic variants are predicted to vastly outnumber common 
variants in the human genome (7, 8). By capturing and sequencing all 
protein-coding exons (i.e., the exome, which comprises ~1-2% of the 
human genome), exome sequencing is a powerful approach for discover-
ing rare variation and has facilitated 
the genetic dissection of unsolved 
Mendelian disorders and studying 
human evolutionary history (9–14). 
Rare and low frequency (MAF be-
tween 0.5%-1%) variants have been 
hypothesized to explain a substantial 
fraction of the heritability of common, 
complex diseases (15). Since common 
variants explain only a modest fraction 
of the heritability of most traits (16, 
17), NHLBI recently sponsored the 
multicenter Exome Sequencing Project 
(ESP), to identify novel genes and 
molecular mechanisms underlying 
complex heart, lung, and blood disor-
ders by sequencing the exomes of a 
large number of individuals measured 
for phenotypic traits of substantial 
public health significance (e.g., early-
onset myocardial infarction, stroke, 
body mass index). 
Data generation and variant dis-
covery. A total of 63.4 terabases of 
DNA sequence was generated at two 
centers with three complimentary defi-
nitions of the exome target and two 
different capture technologies (18). We 
sequenced samples from 14 different 
cohorts in the ESP to an average medi-
an depth of 111x (range 23x – 474x). 
We found no evidence of cohort- 
and/or phenotype specific effects, or 
other systematic biases, in the analysis 
of the filtered SNV data (18; Figs. S1-
S7). Exomes from related individuals 
were excluded from further analysis 
(18; Fig. S8) resulting in a dataset of 
2,440 exomes. We inferred genetic 
ancestry using a clustering approach 
(18), and focused the remaining anal-
yses on the inferred 1,351 EA and 
1,088 AA individuals. We subjected 
the 563,698 variants in the intersection 
of all three capture targets to standard 
quality control filters (18) resulting in a final data set of 503,481 single 
nucleotide variants (SNVs) identified in 15,585 genes and 22.38 Mb of 
targeted sequence per individual. We assessed data quality and error 
rates using complementary strategies (18). Approximately 98% 
(941/961) of all variant sites that were experimentally tested were con-
firmed, including 98% (234/238) of singletons, 98% (678/693) of non-
singleton SNV sites with a MAF < 10%, and 97% (29/30) of SNV sites 
ZLWKD0$) 
The vast majority of coding variation is rare and novel. We ob-
served a total of 503,481 SNVs and 117 fixed, non-reference sites, of 
which 325,843 and 268,903 were found in AA and EA, respectively (18; 
Fig. S9A). Excluding singletons, ~58% of SNVs were population-
specific (93,278 and 32,552 variants were uniquely observed in AA, or 
EA, respectively), and the vast majority of these variants were rare (18; 
Fig. S9B). Most SNVs (292,125 or 58%) were nonsynonymous includ-
ing 285,960 missense variants and 6,165 nonsense variants (18; Fig. 
S9C). Synonymous variants accounted for 38% (188,975) of the total 
SNVs (18; Fig. S9C), with the remaining 4% of SNVs (22,381) located 
Evolution and Functional Impact of 
Rare Coding Variation from Deep 
Sequencing of Human Exomes 
Jacob A. Tennessen,1* Abigail W. Bigham,2*† Timothy D. O’Connor,1* Wenqing 
Fu,1 Eimear E. Kenny,3 Simon Gravel,3 Sean McGee,1 Ron Do,4,5 Xiaoming Liu,6 
Goo Jun,7 Hyun Min Kang,7 Daniel Jordan,8 Suzanne M. Leal,9 Stacey Gabriel,4 
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As a first step toward understanding how rare variants contribute to risk for 
complex diseases, we sequenced 15,585 human protein-coding genes to an average 
median depth of 111x in 2,440 individuals of European (n=1,351) and African 
(n=1,088) ancestry. We identified >500,000 single nucleotide variants (SNVs), the 
majority of which were rare (86% with a minor allele frequency < 0.5%), novel (82%), 
and population-specific (82%). On average, 2.3% of the 13,595 SNVs each person 
carries were predicted to impact protein function of ~313 genes per genome, and 
~95.7% of SNVs predicted to be functionally important were rare. This excess of rare 
functional variants is due to the combined effects of explosive, recent accelerated 
population growth and weak purifying selection. Furthermore, we show that large 
sample sizes will be required to associate rare variants with complex traits. 
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Crohn’s disease and ulcerative colitis are classified as chronic, idi-
opathic inflammatory bowel diseases (IBDs) of the gastrointestinal 
tract with unknown etiology (MIM266600). Crohn’s disease occurs 
in about 100–150 per 100,000 individuals of European a cestry1. 
Generally, the disease affects the ileum and colon, but it can affect any 
region of the gut. Ulcerative colitis has similar population prevalence, 
and although it has some similarities to Crohn’s disease in clinical 
manifestation, the location of inflammation is limited to the colonic 
mucosa. Strong familial aggregation has been observed in twin studies 
of Crohn’s disease and ulcerative colitis2,3. Recent population-based 
sibling risk is 26-fold greater for Crohn’s diseas  and 9-fold greater for 
ulcerative colitis2, and overall Crohn’s disease and ulcerative colitis 
concordance rates in nonselected twin studies are 30% and 15%, 
respectively, among monozygotic twins compared with 4% for 
Crohn’s disease or ulcerative colitis among dizygotic twins3. Like most 
complex diseases, Crohn’s disease and lcerative colitis result from 
a combination of genetic and nongenetic risk factors, and each 
individual factor probably has a modest effect on disease risk4.
Deep resequencing of GWAS loci identifies independent 
rare variants associated with inflammatory bowel disease
Manuel A Rivas1–3, Mélissa Beaudoin4,23, Agnes Gardet5,23, Christine Stevens2,23, Yashoda Sharma6,  
Clarence K Zhang6, Gabrielle Boucher4, Stephan Ripke1,2, David Ellinghaus7, Noel Burtt2, Tim Fennell2,  
Andrew Kirby1,2, Anna Latiano8, Philippe Goyette4, Todd Green2, Jonas Halfvarson9, Talin Haritunians10,  
Joshua M Korn2, Finny Kuruvilla2,11, Caroline Lagacé4, Benjamin Neale1,2, Ken Sin Lo4, Phil Schumm12,  
Leif Törkvist13, National Institute of Diabetes and Digestive Kidney Diseases Inflammatory Bowel Disease 
Genetics Consortium (NIDDK IBDGC)14, United Kingdom Inflammatory Bowel Disease Genetics Consortium14, 
International Inflammatory Bowel Disease Genetics Consortium14, Marla C Dubinsky15, Steven R Brant16,17, 
Mark S Silverberg18, Richard H Duerr19,20, David Altshuler1,2, Stacey Gabriel2, Guillaume Lettre4, Andre Franke7, 
Mauro D’Amato21, Dermot P B McGovern10,22, Judy H Cho6, John D Rioux4, Ramnik J Xavier1,2,5 & Mark J Daly1,2
More than 1,000 susceptibility loci have been identified through genome-wide association studies (GWAS) of common variants; 
however, the specific genes and full allelic spectrum of causal variants underlying these findings have not yet been defined. Here 
we used pooled next-generation sequencing to study 56 genes from regions associated with Crohn’s disease in 350 cases and 350 
controls. Through follow-up genotyping of 70 rare and low-frequency protein-altering variants in nine independent case-control 
series (16,054 Crohn’s disease cases, 12,153 ulcerative colitis cases and 17,575 healthy controls), we identified four additional 
independent risk factors in NOD2, two additional protective variants in IL23R, a highly significant associati n with a protective 
splice varia t in CARD9 (P < 1 × 10−16, odds ratio y 0.29) and additional associations with coding variants in IL18RAP, CUL2, 
C1orf106, PTPN22 and MUC19. We extend the results of successful GWAS by identifying new, rare and probably functional 
variants that could aid functional experiments and predictive models.
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SUMMARY
While it is known that rare copy-number variants
(CNVs) contribute to risk for some neuropsyc iatric
disorders, the role of CNVs in bipolar disorder is
unclear. Here, we reasoned that a contribution of
CNVs to mood disorders might be most evident for
de novo mutations. We performed a genome-wide
an lysis of de novo CNVs in a cohort of 788 rios.
Diagnoses of offspring included bipolar disorder
(n = 185), schizophrenia (n = 177), and healthy
controls (n = 426). Frequencies of de novo CNVs
were significantly higher in bipolar disorder as com-
pared with controls (OR = 4.8 [1.4,16.0], p = 0.009).
De novo CNVs were particularly enriched among
cases with an age at onset younger than 18 (OR =
6.3 [1.7,22.6], p = 0.006). We also confirmed a signifi-
cant enrichment of de novo CNVs in schizophrenia
(OR = 5.0 [1.5,16.8], p = 0.007). Our results suggest
that rare spontaneous mutations are an important
contributor to risk for bipolar diso der and other
major neurop ychiatric diseases.
INTRODUCTION
Bipolar disorder (BD, also known s a ic-depressive illness) is
a severe ood disord r onsisti g of episodes of mania and
epression. The lifetime prevalence of bipolar disorder in the
gen ral population is !1% and the illness i associated with
consid rable morbidity and a high lif time isk of suicide (Meri-
kangas et al., 2011).
Genes play an important r le in risk for BD. Th rate of concor-
dance formonozygotic twins is 40%, comparedwith a 5% rate in
dizygotic twins (Kendler et al., 1995; Kieseppa¨ et al., 2004;
McGuffin et al., 2003), and risk among the first-degree relatives
of individuals with BD is ten-fold greater than risk among the
general population (Barnett and Smoller, 2009). However, as
with other psychiatric disorders, the genetics of BD is complex,
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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more signiﬁcant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the ﬁeld of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as today's DNA sequencing technology has the potential to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a signiﬁcant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efﬁcacious pharmaceutical delivery. To this end, we need to de-
termine how to move forward towards expanded clinical use of this
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
Applied & Translational Genomics xxx (2013) xxx–xxx
Abbreviations: CLIA, Clinical Laboratory Improvements Amendments; NGS, Next
generation sequencing; WGS, whole-genome sequencing.
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• Seguin	E.	1866,	- “our	incomplete	studies	do	
not	permit	actual	classification;	but	it	is	better	
to	leave	things	by	themselves	rather	than	to	
force	them	into	classes	which	have	their	
foundation	only	on	paper”- from	Idiocy	and	its	
treatment	by	the	physiological	method.
• Walter	Frank	Raphael	Weldon	1902	– “the	
accumulation	of	records,	in	which	results	are	
massed	together	in	ill-defined	categories	of	
variable	and	uncertain	extent,	can	only	result	
in	harm”.
OBSERVATIONS ON AN ETHNIC CLASSIFICATION OF IDIOTS *
J. LANGDON H. DOWN M.D., London
THOSE who have given any attention to congenital mental lesions, must have
been frequently puzzled how to arrange, in any satisfactory way, the different
classes of this defect which may have come under their observation. Nor
will the difficulty be lessened by an appeal to what has been written on the
subject. The systems of classification are generally so vague and artificial,
that, not only do they assist but feebly, in any mental arrangement of the
phenomena which are presented, but they completely fail in exerting anypractical influence on the subject.
The medical practitioner who may be consulted in any given case, has,
perhaps in a very early condition of the child's life, to give an opinion on
points of vital importance as to the present condition and probable future of
the little one. Moreover, he may be pressed as to the question, whether the
supposed defect dates from any cause subsequent to the birth or not. Has
the nurse dosed the child with opium? Has the little one met with any
accident? Has the instrumental interference which maternal safety de-
manded, been the cause of what seems to the anxious parents, a vacant future?
Can it be that when away from the family attendant the calomel powders
were judiciously prescribed? Can, in fact, the strange anomalies which the
child presents, be attributed to the numerous causes which maternal solici-
tude conjures to the imagination, in order to account for a condition, for
which any cause is sought, rather than hereditary taint or parental influence.
Will the systems of classification, either all together, or any one of them,
assist the medical adviser in the opinion he is to present, or the suggestions
which he is to tender to the anxious parent? I think that they will entirely
fail him in the matter, and that he will have in many cases to make a guarded
diagnosis and prognosis, so guarded, in fact, as to be almost valueless, or to
venture an authoritative assertion which the future may perhaps confirm.
I have for sometime had my attention directed to the possibility of
making a classification of the feeble minded by arranging them around
various ethnic standards—in other words, framing a natural system to
supplement the information to be derived by an inquiry into the history of
the case.
I have been able to find among the large number of idiots and imbeciles
which come under my observation, both at Earlswood and the out-patient
department of the Hospital, that a considerable portion can be fairly re-
ferred to one of the great divisions of the human family other than the class
from which they have sprung. Of course, there are numerous representatives
of the great Caucasian family. Several well-marked examples of the Ethi-
opian variety have come under my notice, presenting the characteristic
malar bones, the prominent eyes, the puffy lips, and retreating chin. The
* This paper from the London Hospital Clinical Report 3, 259-262 (i866) is republishedon account of its historical interest (see page 698). The editors are indebted to Dr J. H.
Edwards, The Medical School, University of Birmingham who proposed republication and
provided the copy.
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The life expectancy, however, is far below the average, and the tendency is
to the tuberculosis, which I believe to be the hereditary origin of the
degeneracy.Apart from the practical bearing of this attempt at an ethnic classification,
considerable philosophical interest attaches to it. The tendency in the
present day is to reject the opinion that the various races are merely varieties
of the human family having a common origin, and to insist that climatic,
or other influences, are insufficient to account for the different types of man.
Here, however, we have examples of retrogression, or at all events, of de-
parture from one type and the assumption of the characteristics of another.
If these great racial divisions are fixed and definite, how comes it that disease
is able to break down the barrier, and to simulate so closely the features os
the members of another division. I cannot but think that the observations
which I have recorded are indications that the differences in the races are not
specific but variable.
These examples of the result of degeneracy among mankind, appear to me
to furnish some arguments in favour of the unity of the human species.
London Hospital Cli ical Lecture Report. 3, 259-262, i866.
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Medical genetics typically entails the detailed characterization of a patient’s phenotypes followed
by genotyping to discover the responsible gene or mutation. Here, we propose that the systematic
discovery of genetic variants associatedwith complex diseases such as autism are progressing to a
point where a reverse strategy may be fruitful in assigning the pathogenic effects of many different
genes and in determining whether particular genotypes manifest as clinically recognizable pheno-
types. This ‘‘genotype-first’’ approach for complex disease necessitates the development of large,
highly integrated networks of researchers, clinicians, and patient families, with the promise of
improved therapies for subsets of patients.
The genetic study of complex disease has
historically been difficult, meeting with
limited success and often even fewer
therapeutic advances in patient care. Un-
like Mendelian disorders, complex dis-
ease is defined as a phenotype that is
not caused by a single gene mutation
but, rather, by many individual gene
events, with a significant contribution
from environmental factors. The nature
of complex genetic diseasemakes patient
care difficult, as a clinician may never see
two individuals with the same gene muta-
tion and, therefore, the same underlying
genetic etiology. Classical approaches
to the study of complex disease have
identified patientswith similar phenotypes
and have attempted to identify the com-
mon causative mutation for this pheno-
type using association studies. Though
there have been numerous loci reported
over the last 10 years, in most cases,
much of the heritability of complex dis-
ease remains unresolved (Manolio et al.,
2009). The number of success stories
for complex neurocognitive and neuro-
behavioral disease are even fewer, with
enormous numbers of patients (>30,000)
being required to discover a small fraction
of the genetic risk using genome-wide
association study (GWAS) approaches
(McCarroll and Hyman, 2013). Complex
neurodevelopmental disorders, such as
autism, schizophrenia, bipolar disorder,
intellectual disability (ID), and devel-
opmental delay (DD), require better
approaches to link genotype to pheno-
type. In this Essay, we focus on autism
spectrum disorder (ASD)—a highly com-
plex neurodevelopmental disease with a
range of phenotypes and a large patient
base—and propose a gene-centric meth-
odology to model a streamlined approach
for subtyping autism starting with the
genotype (Schulze and McMahon, 2004).
The explosion of data from recent
exome studies (Iossifov et al., 2012; Neale
et al., 2012; O’Roak et al., 2012b; Sanders
et al., 2012) and earlier work on large copy
number variants (CNVs) (de Vries et al.,
2005; Sebat et al., 2007; Sharp et al.,
2006) have emphasized the importance
of sporadic truncating mutations in ASD,
revealing a surprising level of genetic het-
erogeneity among patients. From these
data, it has been estimated that >500
distinct loci may be related to disease
etiology in ASD, assuming a model of
sporadic protein-encoding mutations.
Interestingly, more than two decades
ago, Percy postulated that a ‘‘very wide
variety of autistic syndromes depending
on underlying etiology’’ may exist based
on his observation that a significant frac-
tion of individuals with fragile X, Rett,
and tuberous sclerosis syndromes could
be classified as having autistic features
(Percy et al., 1990). Whereas traditional
genetics approaches were entirely under-
powered to detect small subpopulations
of autism with a common mutant gene,
the advent of next-generation sequencing
technology has made it possible to begin
to systematically classify genetic sub-
types of ASD and, further, to ask whether
these define specific clinical subtypes of
ASD. For the purpose of this Essay, we
will define a ‘‘genetic subtype’’ as a gene
in which recurrent mutations show an
excess of burden in patients versus con-
trols. This is distinguished from a ‘‘molec-
ular subtype’’ that constitutes a group of
genetic subtypes that are linked together
in a common pathway (coexpression,
protein-protein interaction network, etc.)
(O’Roak et al., 2012b).
The extreme genetic heterogeneity
exemplified by autism, we believe, re-
quires a shift in the approach to studying
the genetics of complex neurological
disease. Instead of comprehensive and
exhaustive phenotyping as the first step
to reducing genetic heterogeneity, we
propose to leverage technology to genet-
ically classify subtypes of disease among
patients in whom clinical recontact is
possible. We outline three logical steps
in characterizing genetic subtypes from
the perspective of autism: (1) candidate
discovery and determination of pathoge-
nicity, (2) comprehensive clinical pheno-
typing, and (3) resolution of genetic
872 Cell 156, February 27, 2014 ª2014 Elsevier Inc.
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random mutation modeling40 to calculate the likelihood that observed 
(de novo) mutations have a damaging effect. Similar prioritizations 
are provided by tools that score individual mutation severity (SIFT, 
PolyPhen2, MutationTaster, MutPred, CONDEL, etc.), some of which 
can be adapted to a gene-based prioritization score from genome-wide 
data41. These population data provide a powerful unbiased approach 
to home in on genes that are likely to be among the most penetrant 
because of the complete absence of disruptive variation in the general 
population (for example, CHD8 or DYRK1A). A critical aspect of such 
analyses is the reliability of a particular gene model. Most human 
genes show evidence of alternative splice forms, many of which have 
no known function. Apparent hotspots of mutation for a particular 
exon (often exon-intron boundaries) in both cases and controls may 
suggest misannotation, the presence of a processed pseudogene or an 
alternative, nonfunctional splice form.
Pathway enrichment and links to cancer biology
Another popular approach to discern the most important gene 
candidates for further disease association and characterization has 
been to identify specific biological networks of genes enriched in 
cases as compared to controls. Although this approach cannot be used 
unequivocally to define causality, membership of a specific gene in a 
particular protein-protein interaction (PPI) or coexpression network 
may increase the likelihood of its association with disease. Numerous 
studies have reported significant enrichment of both de novo 
CNV and single-nucleotide variant (SNV) mutations in particular 
pathways3,4,42,43. O’Roak et al.3, for example, reported a significant 
enrichment of de novo disruptive autism mutations among proteins 
associated with chromatin remodeling and B-catenin and WNT 
signaling—a finding that was replicated in a follow-up resequencing 
study of more than 2,400 probands. One recent instance, in which 
membership of a new candidate gene in a PPI network led to the 
discovery of an autism-associated gene, is ADNP. A single ADNP 
LoF mutation was initially observed in exome sequencing studies. 
Although the observed mutation frequency in this gene did not reach 
statistical significance when cases and controls were compared20, 
it was strongly implicated in the PPI network originally defined 
by O’Roak et al.3 Targeted resequencing experiments combined 
with clinical exome sequencing identified several more cases with 
de novo mutations and remarkably similar phenotypes represent-
ing a new SWI-SNF–related autism syndrome (Fig. 3)44. Notably, 
many of the genes implicated in the B-catenin pathway have also been 
described as mutated in patients with ID1 but not in patients with 
SCZ. Similarly, an enrichment of genes interacting with FMR1 (also 
known as FMRP)—the gene responsible for fragile X syndrome—has 
been reported with de novo mutations in ASD5, epilepsy11 and, most 
recently, SCZ10,45. Whether this observation is due to the relative high 
incidence of cases that also presented with comorbid ID remains to 
be determined.
In addition to PPI networks, studies of coexpression have shown 
enrichment for specific spatio-temporal patterns of expression. 
A study of coexpressed genes affected by de novo mutations reported 
an enrichment in fetal prefrontal cortical network in SCZ8, which is 
in line with the finding by Xu et al.9 that genes with higher expression 
Table 4 Recurrent identical de novo mutations in 6 genes identified in 11 exome studies with different neurodevelopmental phenotypes
Gene Coding effect Mutation (genomic DNA level) Mutation (cDNA level)
Mutation  
(protein level) Study Disorder
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser de Ligt et al.1 ID
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser Allen et al.11 EE
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser Allen et al.11 EE
KCNQ3 Missense Chr8(GRCh37):g.133192493G>A NM_001204824.1:c.328C>T p.Arg110Cys Rauch et al.2 ID
KCNQ3 Missense Chr8(GRCh37):g.133192493G>A NM_001204824.1:c.328C>T p.Arg110Cys Allen et al.11 EE
SCN1A Splice donor LRG_8:g.24003G>A NM_006920.4:c.602+1G>A p.? Allen et al.11 EE
SCN1A Splice donor LRG_8:g.24003G>A NM_006920.4:c.602+1G>A p.? Allen et al.11 EE
CUX2 Missense Chr12(GRCh37):g.111748354G>A NM_015267.3:c.1768G>A p.Glu590Lys Rauch et al.2 ID
CUX2 Missense Chr12(GRCh37):g.111748354G>A NM_015267.3:c.1768G>A p.Glu590Lys Allen et al.11 EE
SCN2A Missense Chr2(GRCh37):g.166198975G>A NM_021007.2:c.2558G>A p.Arg853Gln Allen et al.11 EE
SCN2A Missense Chr2(GRCh37):g.166198975G>A NM_021007.2:c.2558G>A p.Arg853Gln Allen et al.11 EE
DUSP15 Missense Chr20(GRCh37):g.30450489G>A NM_080611.2:c.320C>T p.Thr107Met Neale et al.7 ASD
DUSP15 Missense Chr20(GRCh37):g.30450489G>A NM_080611.2:c.320C>T p.Thr107Met Fromer et al.10 SCZ
EE, epileptic encephalopathies; ASD, autism spectrum disorder; ID, intellectual disability; SCZ, schizophrenia.
Figure 1 Genes with recurrent de novo mutations in four 
neurodevelopmental disorders. (a) We estimate the number of fully penetrant 
genes that can explain disease once mutated, based on a de novo model 
using the ‘unseen species problem’. We consider all recurrent missense or 
LoF de novo mutations pathogenic, as well as a defined fraction of mutations 
in genes observed just once (because it is unlikely that all de novo mutations 
are pathogenic). The ratio between genes mutated recurrently and the rate 
of singleton mutations suggests an estimate for the true number of genes 
pathogenic when mutated. Including more singleton mutations increases 
the fraction of each disorder explained by single de novo SNVs at the cost 
of including more genes as pathogenic. Initial exome sequencing studies of 
epilepsy and ID focused on specific pediatric subtypes or the most severe 
cases; thus, the number of generalized epilepsy- or ID-associated genes is 
likely to be much higher. EE, epileptic encephalopathies; ASD, autism spectrum disorder; ID, intellectual disability; SCZ, schizophrenia. (b) Expected  
hit rate (or sensitivity) of true positive genes discovered using trio sequencing studies (under a family-wise error rate of 5%; that is, each gene passes exome-
wide significance of 2.6 × 10−6). We estimate the power of trio sequencing to detect statistically significant associations for disease-associated genes,  
under the assumption that 10% or 20% of singleton mutations could be fully penetrant (vertical bars in a). We assume the distribution of these genes is 
uniform within each disorder and that they do not differ significantly from all genes in terms of length and mutability, although these are taken into account 
when determining significance.
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Recent exome (and genome) sequencing studies of families have aimed 
to comprehensively discover genetic variation to identify the most 
likely causal mutation in patients with disease. Sequencing studies of 
parent-proband trios for probands with intellectual disability (ID)1,2, 
autism spectrum disorder (ASD)3–7, schizophrenia (SCZ)8–10 and epi-
lepsy11 have all suggested that de novo point mutations are important 
in pediatric and adult disorders of brain development (Table 1). The 
relative contribution of de novo mutations to each disorder remains to 
be determined but appears to correlate well with the degree of reduced 
fitness or fecundity of the given condition12. However, not only 
de novo events but also rare inherited copy number variants (CNVs) 
can have an effect on fecundity, though their overall effect on fecundity 
is still debated13. Biologically, 75–80% of de novo point mutations arise 
paternally3,14, likely as a result of the greater number of cell divisions 
in the male germline lineage than in the female lineage. These findings 
are consistent with some epidemiological data that find advancing 
paternal age to be a significant predictor of ASD, ID and SCZ15–17 and 
argue for the need to properly control for paternal age when comparing 
mutation rates between probands and siblings. The importance of 
de novo and private rare mutations is especially important clinically, 
as there are now reports of diagnostic yields ranging from 10–55%  
for select (usually the most severe) groups of patients with ID1,2 and 
epilepsy18, in addition to resolution of unsolved Mendelian disorders19. 
It is clear that next-generation sequencing approaches have provided 
powerful tools for identifying genes harboring potentially pathogenic 
mutations. Deciding which genes to pursue, however, is not always 
self-evident because follow-up research and diagnostic studies are 
critical to understanding the full contribution of a particular mutation 
to its respective phenotype.
In this Review, we will discuss the prioritization of candidate genes 
identified through sequencing studies, show emerging trends and 
highlight potential strategies for subsequent functional characteriza-
tion of these neurodevelopmental genes. We focus on lessons learned 
from 11 recent studies that report 2,368 de novo mutations from a 
total of 2,358 probands and 600 de novo mutations from 731 controls 
(Table 1). The bulk of the data originate from sequencing studies 
of parents and probands with ASD, ID and epileptic encephalopa-
thies, but more recent studies have also highlighted the importance of 
de novo mutations in SCZ. There is evidence that de novo mutations, 
particularly disruptive mutations, occur in the same genes despite the 
nosological distinction for these different diseases. For the purpose of 
this Review, we collectively term these diseases ‘neurodevelopmental 
disorders’ but recognize that some, especially adult-onset diseases 
such as SCZ, may have etiologic components that are not neurode-
velopmental in origin.
Recurrently mutated genes
One of the frequently used concepts in considering possible ‘new 
disease genes’ responsible for a given neurodevelopmental pheno-
type is the recurrence of de novo mutations in the same gene, along 
with the absence of such mutations in healthy controls. This rule 
follows the precedent established for the discovery of pathogenic 
de novo CNVs during the last decade, with the highest priority 
given to recurrent mutations that lead to a complete loss of func-
tion of one of the parental copies of the gene. Up to ten independ-
ent reports of de novo mutations in SCN2A and nine independent 
reports of de novo mutations in SCN1A and STXBP1 have been 
described (Tables 2 and 3). Strikingly, de novo mutations in those 
genes have so far been found exclusively in probands and never in 
controls. Simulation data suggest that at least two but certainly three 
or more recurrent de novo loss-of-function (LoF) events (that is, 
predicted nonsense, frameshift or canonical splice site mutations) 
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Radboud University Medical Center, Nijmegen, The Netherlands. 2Department of 
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Prioritization of ne rodevelopmental disease 
genes by discovery of new mut tions
Alexande  Hoischen1, Niklas Krumm2 & Evan E Eichler2,3
Advances in genome sequencing technologies have begun to revolutionize neurogenetics, allowing the full spectrum of genetic 
variation to be better understood in relation to disease. Exome sequencing of hundreds to thousands of samples from patients 
with autism spectrum disorder, intellectual disability, epilepsy and schizophrenia provides strong evidence of the importance of 
de novo and gene-disruptive events. There are now several hundred new candidate genes and targeted resequencing technologies 
that allow screening of dozens f genes in tens of thousa ds of individuals with h gh specificity and sensitivity. The de ision 
of which genes to pursue depends on many factors, including recurrence, previous evidence of overlap with pathogenic copy 
number variants, the position of the mutation in the protein, the mutational burden among healthy individuals and membership 
of the candidate gene in disease-implicated protein networks. We discuss these emerging criteria for gene prioritization and the 
potential impact on the field of neuroscience.
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CNVs collectively have an appreciable impact on human mental 
health, but their large size often precludes specifying the underlying 
genes involved in the disorder. The pathogenicity of many CNVs 
observed in the clinic is unknown because the typical variant is also 
extremely rare, requiring large surveys to achieve significance in 
case-control cohorts1–4. Large-scale analyses of clinical microarray 
data from children with developmental delay, intellectual disability 
and autism spectrum disorder (ASD) are now possible and have 
been used to catalog regions of human dosage imbalance. In most 
cases, multiple candidate genes still underlie the smallest region of 
overlap. In contrast, exome sequencing studies of parent-child trios 
provide the necessary specificity to discover de novo truncating 
mutations—that is, nonsense and frameshift indel mutations—with 
gene-level specificity5–14. Because of the extreme locus heteroge-
neity of such diseases, however, relatively few recurrences have 
been reported, as surveys of tens of thousands of exomes are still 
prohibitively expensive. As large-scale deletions and truncating 
mutations result in the same dosage imbalance for critical genes, 
we reasoned that systematically integrating both classes of muta-
tion would improve power in discovering genes associated with 
developmental delay. Here we have constructed one of the larg-
est CNV morbidity maps of individuals with intellectual disability, 
developmental delay and/or ASD, both as a clinical resource for 
pathogenic CNVs and also to identify genes potentially sensitive 
to dosage imbalance. We then integrated these data with published 
exome sequencing data and used next-generation sequencing 
methods to rapidly resequence candidate genes in individuals 
with unexplained developmental delay. Using this approach, we 
identified pathogenic mutations in new genes with both statistical 
significance and clinical relevance.
Refining analyses of copy number variation identifies 
specific genes associated with developmental delay
Bradley P Coe1, Kali Witherspoon1, Jill A Rosenfeld2, Bregje W M van Bon3,4, Anneke T Vulto-van Silfhout3, 
Paolo Bosco5, Kathryn L Friend4, Carl Baker1, Serafino Buono5, Lisenka E L M Vissers3,  
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Copy number variants (CNVs) are associated with many neurocognitive disorders; however, these events are typically  
large, and the underlying causative genes are unclear. We created an expanded CNV morbidity map from 29,085 children  
with developmental delay in comparison to 19,584 healthy controls, identifying 70 significant CNVs. We resequenced 26 
candidate genes in 4,716 additional cases with developmental delay or autism and 2,193 controls. An integrated analysis of  
CNV and single-nucleotide variant (SNV) data pinpointed 10 genes enriched for putative loss of function. Follow-up of a subset  
of affected individuals identified new clinical subtypes of pediatric disease and the genes responsible for disease-associated 
CNVs. These genetic changes include haploinsufficiency of SETBP1 associated with intellectual disability and loss of expressive 
language and truncations of ZMYND11 in individuals with autism, aggression and complex neuropsychiatric features.  
This combined CNV and SNV approach facilitates the rapid discovery of new syndromes and genes involved in neuropsychiatric 
disease despite extensive genetic heterogeneity.
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in early fetal life have substantial contribu-
tion to SCZ by de novo mutations. Similarly, 
Willsey et al.46 working with a few high- 
confidence sets of ASD-associated genes as 
seeds reported a convergence of the expres-
sion of these genes in deep-layer cortical 
projection neurons (layers 5 and 6) in mid-
fetal development. Another analysis using a 
larger set of ASD and ID risk genes suggested translational regulation 
by FMR1 and an enrichment in superficial cortical layers43. Implicit 
in these types of analyses is the notion that, while more than 1,000 
genes may be responsible for ASD or ID, in the end the genes will con-
verge on a few highly enriched networks of related genes. It is possible 
that molecular therapies targeted to the network at a specific stage of 
development, as opposed to the individual gene, may be beneficial to 
specific groups of patients.
Related to this, it is intriguing that several recurring genes and 
pathways that have been implicated in neurodevelopmental disease 
have also been associated with different forms of cancer (Fig. 4)47. 
While clear-cut examples such as the mutation of the tumor sup-
pressor genes PTEN (Cowden syndrome) or ARID1B (Coffin-Siris 
syndrome) in neurodevelopmental disease have been extensively 
reviewed48, more recent exome sequencing data from patients with 
neurodevelopmental disease suggest new links. The most striking 
observation here is the identical point mutations reported to cause 
cancer when mutated somatically and severe neurodevelopmental syn-
dromes when mutated in the germline. Examples include the identical 
mutations in SETBP1 (ref. 32), ASXL1 (ref. 49) and EZH2 (ref. 50), as 
well as several genes of the RAS–MAP kinase pathway associated with 
parental-age-effect Mendelian disorders51 (Supplementary Table 1). 
It is important to stress that this is an observation at an individual 
gene level and should not be translated to an epidemiological link: 
that is, this cannot be generalized to speculate that patients with neuro-
developmental disorders in these specific genes will all be at a higher 
risk for certain cancer types. Instead, it is likely that this convergence 
represents a selection of genes that are fundamental to cell biology 
(for example, cell proliferation and/or membership in multi-subunit 
complexes associated with chromatin remodeling). There is also the 
distinct possibility of pleiotropy; that is, the genes and pathways have 
completely unrelated functions, explaining developmental defects and 
cancer independently. Therefore, de novo mutations in those genes 
can result in different outcomes depending on timing, genetic back-
ground and cellular context. Nevertheless, there may be advantages 
to integrating sequence data from patients with neurodevelopmental 
disease and massive sequencing programs devoted to the discovery of 
somatic mutations in tumors—for example, the International Cancer 
Genome Project52. It is possible that these intersections will help to 
further prioritize genes important in both cellular development and 
neurodevelopment.
Phenotypic similarity of recurrent de novo mutations
Although essential, statistical support of recurrent mutations is 
not the sole arbiter in determining pathogenicity of particular 
mutations and genes. In particular, it is important to consider the 
phenotypic presentation and overlap of the individuals with the same 
presumptive underlying genetic lesion. In this regard, we note that 
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Figure 2 CNV and exome intersections define 
candidate genes. (a,b) Deletion (red) and 
duplication (blue) burden for developmental 
delay or ID cases and controls for two genes, 
DYRK1A (a) and MBD5 (b), as compared to 
sporadic LoF mutations on the basis of exome 
sequencing of 209 autism simplex trios. DYRK1A 
is a strong candidate gene for cognitive deficits 
associated with Down syndrome; LoF mutations 
are associated with minibrain phenotype in 
Drosophila65, autism-like behavior in mouse64 
and a deletion syndrome in humans27,63. MBD5 
has been implicated as the causal gene for 
the 2q23.1 deletion syndrome associated with 
epilepsy, autism and ID91,92.
a bFigure 3 Phenotypic similarity of two patients 
with identical PACS1 de novo mutations and two 
patients with similar ADNP mutations. (a) These 
two unrelated patients show identical de nov  
point mutations (c.607C>T; p.Arg203Trp) in 
PACS1 (RefSeq NM_018026.3)53. The striking 
similarity in phenotype includes low anterior 
hairline, highly arched eyebrows, synophrys, 
hypertelorism with downslanted palpebral 
fissures, long eyelashes, a b lbous nasal tip, a 
flat philtrum with a thin upper lip, downturned 
corners of the mouth and low-set ears. Reprinted 
from ref. 53, Copyright (2012), with permission from The American Society of Human Genetics. (b) These two unrelated patients both show LoF mutations 
in ADNP (c.2496_2499delTAAA; p.Asp832Lysfs*80 and c.2157C>G; p.Tyr719*)44 resulting in a new SWI-SNF–related autism syndrome. Patients present 
with clinical similarities, including a prominent forehead, a thin upper lip and a broad nasal bridge. Reprinted from ref. 44.
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CNVs collectively have an appreciable impact on human mental 
health, but their large size often precludes specifying the underlying 
genes involved in the disorder. The pathogenicity of many CNVs 
observed in the clinic is unknown because the typical variant is also 
extremely rare, requiring large surveys to achieve significance in 
case-control cohorts1–4. Large-scale analyses of clinical microarray 
data from children with developmental delay, intellectual disability 
and autism spectrum disorder (ASD) are now possible and have 
been used to catalog regions of human dosage imbalance. In most 
cases, multiple candidate genes still underlie the smallest region of 
overlap. In contrast, exome sequencing studies of parent-child trios 
provide the necessary specificity to discover de novo truncating 
mutations—that is, nonsense and frameshift indel mutations—with 
gene-level specificity5–14. Because of the extreme locus heteroge-
neity of such diseases, however, relatively few recurrences have 
been reported, as surveys of tens of thousands of exomes are still 
prohibitively expensive. As large-scale deletions and truncating 
mutations result in the same dosage imbalance for critical genes, 
we reasoned that systematically integrating both classes of muta-
tion would improve power in discovering genes associated with 
developmental delay. Here we have constructed one of the larg-
est CNV morbidity maps of individuals with intellectual disability, 
developmental delay and/or ASD, both as a clinical resource for 
pathogenic CNVs and also to identify genes potentially sensitive 
to dosage imbalance. We then integrated these data with published 
exome sequencing data and used next-generation sequencing 
methods to rapidly resequence candidate genes in individuals 
with unexplained developmental delay. Using this approach, we 
identified pathogenic mutations in new genes with both statistical 
significance and clinical relevance.
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candidate genes in 4,716 additional cases with developmental delay or autism and 2,193 controls. An integrated analysis of  
CNV and single-nucleotide variant (SNV) data pinpointed 10 genes enriched for putative loss of function. Follow-up of a subset  
of affected individuals identified new clinical subtypes of pediatric disease and the genes responsible for disease-associated 
CNVs. These genetic changes include haploinsufficiency of SETBP1 associated with intellectual disability and loss of expressive 
language and truncations of ZMYND11 in individuals with autism, aggression and complex neuropsychiatric features.  
This combined CNV and SNV approach facilitates the rapid discovery of new syndromes and genes involved in neuropsychiatric 
disease despite extensive genetic heterogeneity.
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to that expected with intersections by random chance (OR = 1.15, 
95% confidence interval (CI) = 0.8–1.6; P = 1, Fisher’s exact test). 
However, when we limited our analysis to the 21 genes with 2 or 
more truncating mutations in probands, we observed significant dele-
tion enrichment for 33.3% of the genes (7 of 21 genes; OR = 2.72; 
P = 0.034, Fisher’s exact test), supporting the notion that integrat-
ing CNV data and exome sequencing data increases power to detect 
disease-related genes. Using a statistical framework based on a hyper-
geometric distribution, we computed a joint probability of putative 
loss of function (Online Methods), combining the CNV data with 
the SNV data for the 6,500 individuals from the Exome Sequencing 
Project (ESP) (ESP6500 controls) and published de novo loss-of- 
function mutations in probands. This analysis highlighted 38 of the 
247 genes with nominally significant increases in loss-of-function 
events in cases in comparison to controls (19 with q value a 0.01), 
including 13 genes previously identified as disease causing (Online 
Mendelian Inheritance in Man, OMIM) (Table 2).
Targeted resequencing of candidate genes in ASD and 
intellectual disability
On the basis of the analyses above, we selected a set of 26 candidate 
genes with significant CNV enrichment, rare focal CNVs with de novo 
mutations from exome sequencing studies and top candidates from 
targeted resequencing in ASD and/or intellectual disability (Table 3). 
For three of these regions, we selected at least two adjacent genes map-
ping within the SRO; we also selected six genes (GRIN2B, ARID1B, 
MBD5, PTEN, SCN1A and KANSL1) known to be associated with 
ASD and/or intellectual disability as positive controls30–35. We used 
molecular inversion probe (MIP)-based capture36 to sequence the 26 
genes in 3,387 cases of intellectual disability and/or developmental 
Table 2 Intersection of CNV and exome data
Gene Isoform
Exome data Array CGH
Combined  
LoF P value
Combined  
LoF q valuee
1,879  
published  
cases LoF
1,879 published 
cases de novo 
LoF (ESP average 
read depth >20, 
Dustmasked)
6,500 ESP LoF 
(ESP average 
read depth >20, 
Dustmasked)
Signature  
deletions  
(n = 29,085)
Control  
deletions  
(n = 19,584)
ANK2a NM_020977.3b 1 1 0 5 0 0.0171 0.169
ARHGAP5 NM_001030055.1 1 1 0 7 0 0.0061 0.0833
BCL11A NM_022893.3 1 0 0 4 0 0.0286 0.244
CAPRIN1 NM_005898.4 1 1 0 4 0 0.0286 0.244
CARKD NM_001242881.1c 1 1 0 12 4 0.0363 0.28
CHD2a NM_001271.3 3 3 0 0 0 0.0113 0.127
CHD8a NM_001170629.1 3 3 0 2 0 0.00402 0.0703
CSDE1 NM_001130523.2 1 1 0 3 0 0.0479 0.311
CUL3a NM_003590.4 2 2 0 5 0 0.00383 0.0703
DLL1 NM_005618.3 1 0 0 32 1 2.17 × 10−7 2.68 × 10−5
DYRK1Aa NM_001396.3 2 2 0 11 0 1.74 × 10−4 8.60 × 10−3
FAM8A1 NM_016255.2 1 1 0 5 0 0.0171 0.169
FOXP1a NM_001244810.1 1 1 0 4 0 0.0286 0.244
GRIN2Ba NM_000834.3 3 3 0 2 0 0.00402 0.0703
GTPBP4 NM_012341.2 1 1 0 3 0 0.0479 0.311
LTN1 NM_015565.2 1 1 0 6 0 0.0102 0.12
MBD5a NM_018328.4 1 1 0 16 6 0.0343 0.273
MYT1L NM_015025.2 1 1 0 8 0 0.00365 0.0703
NAA15 NM_057175.3 2 2 0 5 3 0.0296 0.244
NCKAP1 NM_205842.1 2 2 0 7 0 0.00137 0.0564
NFIA NM_001134673.3 1 1 0 3 0 0.0479 0.311
NRXN1a NM_001135659.1 1 1 0 30 9 0.00427 0.0703
NTM NM_001144058.1 1 1 0 40 0 2.53 × 10−10 6.25 × 10−8
PCOLCE NM_002593.3 1 1 0 7 0 0.0061 0.0833
PHF2 NM_005392.3 1 1 0 4 0 0.0286 0.244
RAB2A NM_002865.2 1 1 0 3 0 0.0479 0.311
SCN1Aa NM_001165963.1 4 4 0 10 1 7.36 × 10−5 4.55 × 10−3
SCN2Aa NM_021007.2 6 5 0 10 0 7.34 × 10−7 6.04 × 10−5
SLC6A1 NM_003042.3 1 1 0 6 0 0.0102 0.12
SRM NM_003132.2 1 1 0 9 0 0.00218 0.0703
STXBP1a NM_003165.3 2 2 0 4 0 0.00641 0.0833
SUV420H1 NM_016028.4d 1 1 0 3 0 0.0479 0.31135
SYNGAP1a NM_006772.2 4 4 0 0 1 0.00252 0.0703
TBR1 NM_006593.2 2 2 0 7 1 0.00522 0.0806
UBN2 NM_173569.3 1 1 0 5 0 0.0171 0.169
WAC NM_016628.4 1 1 0 3 0 0.0479 0.31135
WDFY3 NM_014991.4 1 1 0 8 0 0.00365 0.0703
ZMYND11 NM_006624.5 1 1 0 8 0 0.00365 0.0703
LOF, loss of function.
aDisease gene in OMIM. bVariant 2; this is the major form of ankyrin in the adult brain. cVariant 2; this isoform and variants 3 and 4 are shorter than variant 1. dVariant 2; this isoform is shorter 
and has a distinct C terminus in comparison to isoform 1. ePlease see the Supplementary Note for discussion of the q values shown.
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delay and 1,329 cases of ASD, totaling 4,716 cases. Putative loss-of-
function SNVs and indels were validated by Sanger sequencing and 
assessed in parental DNA, when available, to determine inheritance. 
Genes with significant enrichment were identified by comparison 
with the MIP resequencing data for 2,193 unaffected siblings from 
the Simons Simplex Collection37 and ESP6500. We tested each gene 
for combined enrichment of loss-of-function variation across CNV 
and SNV data (Online Methods) and identified 16 genes (Table 3 and 
Supplementary Table 5) with a significant enrichment of disruptive 
mutations in cases. Additionally, to control for the differential effects 
of terminal truncating events, we applied a statistical model based 
on predicted protein lengths for genes with truncating or splice-site 
events in ESP6500 (Supplementary Fig. 5), as this approach was com-
plementary to the results from case-control 
comparison (Table 3).
Among the positive controls, our analy-
sis confirmed the pathogenicity of five genes 
using a nominal threshold of significance on 
the joint P values: ARID1B (five CNVs and 
nine truncating SNVs, one of which was 
confirmed to be de novo; P = 1.51 × 10−4, 
q = 6.54 × 10−4), GRIN2B (two CNVs—one focal CNV disrupting 
the distal end of GRIN2B—and four new truncating variants; P = 
0.00546, q = 0.0142) and MBD5 (P = 0.0429, q = 0.0744), as well 
as SCN1A (P = 0.0036, q = 0.0117), in comparison to the adjacent 
gene TTC21B (P = 1.00, q = 1.00). Integration of SNV and CNV 
data confirmed KANSL1 as the gene responsible for the 17q21.31 
deletion syndrome32 (P = 0.000418, q = 0.00155) in comparison 
to the adjacent gene MAPT (P = 0.36, q = 0.455) (Table 3 and 
Supplementary Table 5). Clinical follow-up for one KANSL1 case 
with a severe frameshift demonstrated striking phenotypic resem-
blance to microdeletion carriers, confirming this gene as the major 
contributor to the phenotype of 17q21.31 microdeletion (Koolen– 
de Vries) syndrome32,38.
Table 4 Brief phenotypic description of cases with SETBP1 loss-of-function variants
Case
Age at  
examination Sex Alteration Inheritance Cognitive
Hyperactive 
or ADHD
Social  
difficulties
Other  
behavioral  
difficulties
Speech 
delay
Motor  
delay
Facial  
dysmorphism
Seizures  
or EEG  
abnormalities
DNA03-00335 14 years M p.Ile822Tyrfs*13 De novo Normal IQ + + + +
DNA-008897 73 years M p.Leu411Glyfs*6 Profound ID + + + + +
Troina 1274 19 years M p.Trp532* De novo Severe ID + + + + −
Troina 1512 17 years M p.Ser1011* De novo Mild ID + (3y 8m) + + + + −
Troina 3097 34 years F p.Arg143Valfs*64 Severe ID + + + +
DNA11-21308Z 36 years F p.Arg625* Mild to  
moderate ID
+ + + + + +
DNA11-19324Z 9 years F p.Arg626* 2- to 2.5-year 
delay at  
9 years old
+ − + −
DNA08-08272 9 years M p.Gly15Argfs*47 Mild ID + + + + + +
Rauch et al. 13 years F p.Lys592* Mild ID + + + − +
9886269 5 years M Deletion De novo Global delay + + + + +
Marseglia et al. 15 years M Deletion De novo Mild ID + + + + + + +
Filges et al. pt. 1 7 years M Deletion De novo Moderate ID + + + +
Filges et al. pt. 2 4 years M Deletion De novo + + +
ID, intellectual disability;  EEG, electroencephalogram; M, male; F, female.
1
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1,597
SETSKI
p.Gly15Argfs*47
p.Arg143Valfs*64
p.Leu411Glyfs*6
p.Trp532* p.Arg625*
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p.Ser1011*p.Lys592* p.Ile822Tyrfs*13
a
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c
Filges et al.
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SLC14A2
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Marseglia  et al.
18q12.3
Chr. 18
Scale
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SETBP1
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3 years, 8 months
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SETBP1 p.Ile822Tyrfs*13
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Figure 1 Truncating SETBP1 mutations and 
associated phenotypes. (a) CNV data define a focal 
CNV region around SETBP1. Combining a focal 
de novo deletion observed in our study (9886269) 
with CNVs from Filges et al.41 and Marseglia et al.42  
(red bars) highlights minimal common regions, 
including SETBP1 and LINC01478. (b) Targeted 
resequencing identified eight truncating variants 
in SETBP1 and none in controls. Integration of 
published exome data identified one additional 
case and no truncating events in controls.  
Ath, AT hook; SKI, SKI-homologous region;  
SET, SET-binding domain; Rpt, repeat. (c) Phenotypic 
assessment (summarized in Table 4) identified 
a recognizable phenotype, including IQ deficits 
ranging from mild to severe, impaired speech and 
distinctive facial features. See the Supplementary 
Note for additional photographs of affected 
individuals and clinical descriptions. We obtained 
informed consent to publish the photographs.
©
20
14
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
NATURE GENETICS ADVANCE ONLINE PUBLICATION 5
A RT I C L E S
delay and 1,329 cases of ASD, totaling 4,716 cases. Putative loss-of-
function SNVs and indels were validated by Sanger sequencing and 
assessed in parental DNA, when available, to determine inheritance. 
Genes with significant enrichment were identified by comparison 
with the MIP resequencing data for 2,193 unaffected siblings from 
the Simons Simplex Collection37 and ESP6500. We tested each gene 
for combined enrichment of loss-of-function variation across CNV 
and SNV data (Online Methods) and identified 16 genes (Table 3 and 
Supplementary Table 5) with a significant enrichment of disruptive 
mutations in cases. Additionally, to control for the differential effects 
of terminal runcating events, we appli d a statistical model based 
on predicted protein lengths for genes with truncating or splice-site 
events in ESP6500 (Supplementary Fig. 5), as this approach was com-
plementary to the results from case-control 
comparison (Table 3).
Among the positive controls, our analy-
sis confirmed the pathogenicity of five genes 
using a nominal threshold of significance on 
the joint P values: ARID1B (five CNVs and 
nine truncating SNVs, one of which was 
confirmed to be de novo; P = 1.51 × 10−4, 
q = 6.54 × 10−4), GRIN2B (two CNVs—one focal CNV disrupting 
the distal end of GRIN2B—and four new truncating variants; P = 
0.00546, q = 0.0142) and MBD5 (P = 0.0429, q = 0.0744), as well 
as SCN1A (P = 0.0036, q = 0.0117), in comparison to the adjacent 
gene TTC21B (P = 1.00, q = 1.00). Integration of SNV and CNV 
data confirmed KANSL1 as the gene responsible for the 17q21.31 
deletion syndrome32 (P = 0.000418, q = 0.00155) in comparison 
to the adjacent gene MAPT (P = 0.36, q = 0.455) (Table 3 and 
Supplementary Table 5). Clinical follow-up for one KANSL1 case 
with a severe frameshift demonstrated striking phenotypic resem-
blance to microdeletion carriers, confirming this gene as the major 
contributor to the phenotype of 17q21.31 microdeletion (Koolen– 
de Vries) syndrome32,38.
Table 4 Brief phenotypic description of cases with SETBP1 loss-of-function variants
Case
Age at  
examination Sex Alteration Inheritance Cognitive
Hyperactive 
or ADHD
Social  
difficulties
Other  
behavioral  
difficulties
Speech 
delay
Motor  
delay
Facial  
dysmorphism
Seizures  
or EEG  
abnormalities
DNA03-00335 14 years M p.Ile822Tyrfs*13 De novo Normal IQ + + + +
DNA-008897 73 years M p.Leu411Glyfs*6 Profound ID + + + + +
Troina 1274 19 years M p.Trp532* De novo Severe ID + + + + −
Troina 1512 17 years M p.Ser1011* De novo Mild ID + (3y 8m) + + + + −
Troina 3097 34 years F p.Arg143Valfs*64 Severe ID + + + +
DNA11-21308Z 36 years F p.Arg625* Mild to  
moderate ID
+ + + + + +
DNA11-19324Z 9 years F p.Arg626* 2- to 2.5-year 
delay at  
9 years old
+ − + −
DNA08-08272 9 years M p.Gly15Argfs*47 Mild ID + + + + + +
Rauch et al. 13 years F p.Lys592* Mild ID + + + − +
9886269 5 years M Deletion De novo Global delay + + + + +
Marseglia et al. 15 years M Deletion De novo Mild ID + + + + + + +
Filges et al. pt. 1 7 years M Deletion De novo Moderate ID + + + +
Filges et al. pt. 2 4 years M Deletion De novo + + +
ID, intellectual disability;  EEG, electroencephalogram; M, male; F, female.
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Figure 1 Truncating SETBP1 mutations and 
associated phen types. (a) CNV ata d fine a focal 
CNV region around SETBP1. Combining a focal 
de novo deletion observed in our study (9886269) 
with CNVs from Filges et al.41 and Marseglia et al.42  
(red bars) highlights minimal common regions, 
including SETBP1 and LINC01478. (b) Targeted 
resequencing identified eight truncating variants 
in SETBP1 and none in controls. Integration of 
published exome data identified one additional 
case and no truncating events in controls.  
Ath, AT hook; SKI, SKI-homologous region;  
SET, SET-binding domain; Rpt, repeat. (c) Phenotypic 
assessment (summarized in Table 4) identified 
a recognizable phenotype, including IQ deficits 
ranging from mild to severe, impaired speech and 
distinctive facial features. See the Supplementary 
Note for additional photographs of affected 
individuals and clinical descriptions. We obtained 
informed consent to publish the photographs.
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delay and 1,329 cases of ASD, totaling 4,716 cases. Putative loss-of-
function SNVs and indels were validated by San er sequencing and 
assessed in parental DNA, when available, to determine inheritance. 
Genes with significant enrichment were identifie  by comparison 
with the MIP resequencing data for 2,193 unaff cted siblings from 
th  Simons Simplex Collection37 and ESP6500. We tested each gen  
for combi ed e richment of loss-of-function a iation acro s CNV 
and SNV data (Online Methods) and identified 16 genes (Table 3 and 
Suppleme tary Table 5) with a significant enrichme t of disruptive 
mutations in cases. Additionally, to control for the differential effects 
of terminal truncating ev nts, w  applied a statistical model based 
on predicted protein l gths for genes with tr ati g o  splice-site 
events in ESP6500 (Supplementary Fig. 5), as this approach was com-
plementary to th  results from case-control 
comparison (Table 3).
Among the positive controls, our analy-
sis confirmed the pathogenicity of five genes 
using a nominal thresh ld of significance on 
the joint P values: ARID1B (five CNVs and 
nine truncating SNVs, one of which was 
confirmed to be de novo; P = 1.51 × 10−4, 
q = 6.54 × 10−4), GRIN2B (two CNVs—one focal CNV disrupting 
the distal end of GRIN2B—and f ur new truncating variants; P = 
0.00546, q = 0.0142) and MBD5 (P = 0.0429, q = 0.0744), as well 
as SCN1A (P = 0.0036, q = 0.0117), in comparison to the adjacent 
gene TTC21B (P = 1.00, q = 1.00). Integration of SNV and CNV 
data confirmed KANSL1 as the gene responsible for the 17q21.31 
deletion syndrom 32 (P = 0.000418, q = 0.00155) in omparison 
to the adjacent gene MAPT (P = 0.36, q = 0.455) (Table 3 and 
Supplementary Table 5). Clinical follow-up for one KANSL1 case 
with a severe frameshift demonstrated striki g phen typic resem-
blance to micr deletion carriers, confirming thi  ge e as the major 
contributor to the phenotype of 17q21.31 microdeletion (Koolen– 
de Vries) syndrome32,38.
Table 4 Brief phenotypic description of cases with SETBP1 loss-of-function variants
Case
Age at  
examination Sex Alteration Inheritance Cognitive
Hyperactive 
or ADHD
Social  
difficulties
Other  
behavioral  
difficulties
Speech 
delay
Motor  
delay
Facial  
dysmorphism
Seizures  
or EEG  
abnormalities
DNA03-00335 14 years M p.Ile822Tyrfs*13 De novo Normal IQ + + + +
DNA-008897 73 years M p.Leu411Glyfs*6 Profound ID + + + + +
Troina 1274 19 years M p.Trp532* De novo Severe ID + + + + −
Troina 1512 17 years M p.Ser1011* De novo Mild ID + (3y 8m) + + + + −
Troina 3097 34 years F p.Arg143Valfs*64 Severe ID + + + +
DNA11-21308Z 36 years F p.Arg625* Mild to  
moderate ID
+ + + + + +
DNA11-19324Z 9 years F p.Arg626* 2- to 2.5-year 
delay at  
9 years old
+ − + −
DNA08-08272 9 years M p.Gly15Argfs*47 Mild ID + + + + + +
Rauch et al. 13 years F p.Lys592* Mild ID + + + − +
9886269 5 years M Deletion De novo Global delay + + + + +
Marseglia et al. 15 years M Deletion De novo Mild ID + + + + + + +
Filges et al. pt. 1 7 years M Deletion De novo Moderate ID + + + +
Filges et al. pt. 2 4 years M Deletion De novo + + +
ID, intellectual disability;  EEG, electroencephalogram; M, male; F, female.
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Figure 1 Tru cating SETBP1 mutations and 
associated phenotypes. (a) CNV data define a focal 
CNV region around SETBP1. Combining a focal 
de novo deletion observed in our study (9886269) 
with CNVs from Filges et al.41 and Marseglia et al.42  
(red bars) highlights minimal common regions, 
including SETBP1 and LINC01478. (b) Targeted 
resequencing identified eigh  truncating variants 
i  SETBP1 and none in controls. Integration of 
published xome ata identifi d one additional 
case and no truncating events in controls.  
Ath, AT hook; SKI, SKI-homologous regi n;  
SET, SET-binding domain; Rpt, repeat. (c) Phenotypic 
assessment (summarize  i  Table 4) identified 
a recognizable phenotype, including IQ deficits 
ranging from mild to severe, impaired speech and 
distinctive faci l features. See th  Suppleme tary 
Note for additional photographs of affected 
individuals and clinical descriptions. We obtained 
informed consent to publish the photographs.
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An enrichment of loss-of-function mutations in cases was observed 
for ten additional genes (ADNP, DYRK1A, NRXN1, NRG3, SETBP1, 
ZMYND11, DNM3, CYFIP1, FOXP1 and SCN2A) (Table 4). In one 
case with a de novo DYRK1A splice-site mutation (see Troina1818 
in Supplementary Table 5), the affected individual presented with 
severe microcephaly, consistent with published autism-related 
de novo truncating mutations and CNVs from earlier studies36,39. 
Among the genes for which there was no enrichment in cases ver-
sus controls, two were notable: CHD1L and ACACA—candidates 
for the 1q21 deletion and 17q12 deletion syndromes, respectively40. 
In our resequencing study of CHD1L, for example, we identified 
14 likely truncating variants (Table 3) in comparison to 9 inde-
pendent truncating variants in controls, which indicates that rare 
truncating mutations of CHD1L are not uncommon (Table 3 and 
Supplementary Table 5). There was also no significant decrease in 
the predicted protein size in cases in comparison to controls (P = 0.94, 
log-rank test).
Phenotypic examination of cases with SETBP1 and ZMYND11 
truncations
Among the significant genes, we focused on SETBP1 and ZMYND11 
for further phenotypic characterization. We confirmed a focal de novo 
deletion and five cases with truncating mutations (three tested and 
confirmed to be de novo) in the SETBP1 gene (encoding SET-binding 
protein 1). Disruptive mutations were absent in controls, with 
the exception of a splice-site alteration predicted to lead to the loss 
of an in-frame exon encoding 18 amino acids. Notably, all truncat-
ing mutations in cases occurred in cohorts of intellectual disability, 
where we observed an enrichment of mutations (P = 0.0093, joint 
loss of function) and decreased predicted protein size (P = 0.011, 
log-rank test) (Fig. 1, Table 3 and Supplementary Tables 5 and 6). 
Integration of our variants from cases with 2 additional truncating 
variants found in a separate genetic screen for intellectual disability 
(n = 847) with the same MIPs, as well as published small deletions 
and de novo variants, highlighted a similar phenotype for the affected 
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c
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Figure 2 Truncating ZMYND11 mutations and associated phenotypes. (a) CNV data refine a focal CNV deletion region (red bars) containing two genes 
(ZMYND11 and DIP2C). (b) Targeted resequencing identified five truncating variants and one single-amino-acid deletion predicted to behave as loss-
of-function variants by removing a critical binding residue in the MYND domain (Gln587). Analysis of control resequencing and exome data identified 
no additional truncating events in ZMYND11 but highlighted two truncating mutations in DIP2C. PHD, plant homeodomain; Bromo, bromodomain; 
PWWP, conserved ProTrpTrpPro motif; NLS, nuclear localization sequence; MYND, zinc finger MYND type (myeloid, Nervy and DEAF-1); DMAP, DNA 
methyltransferase–associated protein; CaiC, crotonobetaine/carnitine-CoA ligase; AMP, AMP-dependent synthetase/ligase. (c) Phenotypic assessment 
(summarized in Table 5) showed a consistent phenotype characterized by mild intellectual disability accompanied by speech and motor delays, as 
well as complex neuropsychiatric behavioral and characteristic facial features. See the Supplementary Note for additional photographs of the affected 
individuals and clinical descriptions. We obtained informed consent to publish the photographs.
Researchers	develop	genetic	profile	of	
the	Netherlands
• “The	Genome	of	the	Netherlands	can	greatly	
accelerate	research	into	genes	that	play	a	key	role	
in	the	development	of	chronic	and	age-related	
diseases.	We	can	now	focus	specifically	on	the	
disease-causing	genes”.
• “A	noticeable	result	is	that	every	participant	in	
this	research	on	average	turned	out	to	have	
twenty	mutations	that	were	thought	to	cause	
rare	diseases,	although	the	participants	were	
perfectly	healthy”.
http://medicalxpress.com/news/2014-06-genetic-profile-netherlands.html

“There	are	~12	billion	nucleotides	in	every	cell	of	the	human	body,	and	there	are	
~25-100	trillion	cells	in	each	human	body.	Given	somatic	mosaicism,	epigenetic	
changes	and	environmental	differences,	no	two	human	beings	are	the	same,	
particularly	as	there	are	only	~7	billion	people	on	the	planet”.	


In	the	year	2014….
This:
Is	orders	of	magnitudes	easier	than	
this:
Clinical	Validity	with	Worldwide	
Human	Genetic	Variation	“database”?
PatientsLikeMe
100,000	British	Genomes
Clinical	Validity?
This	is	SO	complex	that	the	only	solid	
way	forward	is	with	a	“networking	of	
science”	model,	i.e.	online	database	
with	genotype	and	phenotype	
longitudinally	tracked	for	thousands	of	
volunteer	families.
PatientsLikeMe
Lost	in	Translation
• We	need	to	focus	on	the	extremes,	i.e.	severe	illness,	
not	just	the	“average”	person,	i.e.	a	new	focus	on	rare	
variant	diseases	uncovers	fundamentally	important	
biological	processes.
• Many	exciting	genetic	discoveries	are	being	made	and	
published.
• There	is	much	fanfare	and	media	coverage.
• But,	then	the	genetic	researchers	move	on	to	the	next	
disease,	expecting	someone	else	will	engage	with	the	
families	and	perform	counseling,	education	and	carrier	
screening.
• This	does	not	happen	mostly	(certainly	not	always).	
• Only	0.5%	of	the	38	MILLION	published	papers	are	cited	
more	than	200	times,	and	HALF	are	never	cited	(from	
Topol,	Creative	Destruction	of	Medicine,	2012).
Systemic	Barriers
• Sometimes	just	simple	lack	of	communication	
between	researchers	and	the	physicians	and	
genetic	counselors.
• We	only	have	1500	medical	geneticists	and	2000	
certified	genetic	counselors	for	310	million	
people	in	America!	
• Insurance	will	often	deny	coverage	of	genetic	
testing,	particularly	for	novel	mutations,	so	
genetic	testing	is	much	under-utilized	relative	to	
procedure-based	medicine.
Systemic	Barriers	cont….
• Physicians	and	health	care	system	woefully	
uneducated	regarding	genetics.
• Current	sequencing	(exomes and	whole	
genomes)	being	sequenced	in	random	
laboratories	with	no	clinical	standards	in	place	
(although	people	trying	to	change	this).
Cystic	Fibrosis	
• Gene	cloned	in	1989	
• Finally,	drugs	screened	in	human	cells,	restoring	CFTR	
function,	in	particular	mutated	version,	G551D.
• Trials	for	one	mutated	version	G551D,	present	in	4%	of	
CF	patients.	The	drug	worked.
• FDA	approval	in	record	time.
• Cost	of	Drug?	$294,000	per	year,	to	be	taken	for	a	
lifetime.	For	60	years,	that	is	~$18	million	per	person.
• 4%	of	30,000	people	with	CF	in	US	=	1200.
• So,	$21.6	billion	to	treat	1200	people	for	60	years	
(assuming	lower	than	average	lifespan).
• From	2000-2004,	82	children	born	with	CF	in	Victoria,	Australia.	
• 5	of	these	(6%)	were	from	families	with	known	history	of	CF.
• Even	when	a	family	history	is	known,	most	relatives	do	not	undertake	
carrier	testing.	In	an	audit	of	cascade	carrier	testing	after	a	diagnosis	of	
CF	through	newborn	screening,	only	11.8%	of	eligible	(non-parent)	
(82/716)	relatives	were	tested.
• The	other	94%	could	have	been	prevented	with	carrier	screening	too.


